Log In
Print
BCIQ
Print
Print this Print this
 

otlertuzumab (TRU-016)

  Manage Alerts
Collapse Summary General Information
Company Emergent BioSolutions Inc.
DescriptionHumanized ADAPTIR molecule that targets the CD37 antigen
Molecular Target CD37
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat previously untreated chronic lymphocytic leukemia (CLL); Treat relapsed and refractory chronic lymphocytic leukemia (CLL); Treat relapsed chronic lymphocytic leukemia (CLL)
Regulatory Designation U.S. - Orphan Drug (Treat relapsed chronic lymphocytic leukemia (CLL));
EU - Orphan Drug (Treat relapsed chronic lymphocytic leukemia (CLL))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$342.0M

$126.8M

$215.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today